The Impact of WeChat Group Patient Education on the Eradication Rate of Helicobacter Pylori
The Impact of Interactive Patient Education Based on WeChat Group on the Eradication Rate of Helicobacter Pylori
1 other identifier
interventional
438
1 country
1
Brief Summary
In this study, effects of oral and written education, WeChat education plus oral and written education on Helicobacter pylori eradication will be compared in a randomized way.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Jul 2021
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 7, 2021
CompletedFirst Posted
Study publicly available on registry
April 20, 2021
CompletedStudy Start
First participant enrolled
July 23, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 10, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
September 10, 2022
CompletedJanuary 31, 2023
January 1, 2023
1 year
April 7, 2021
January 28, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
eradication rate in each group
Six weeks after completion of treatment,number of patients get H.pylori eradicated supported by negative 13C-UBT results will be investigated by an independent researcher.Then eradication rate in each group will be calculated by using intention-to-treat analysis and per-protocol analysis.
2 months
Secondary Outcomes (1)
prevalence of adverse events
14 days
Other Outcomes (1)
compliance of patients in the two groups
14 days
Study Arms (2)
Control group
OTHERPatients in this group will receive clarithromycin based bismuth-containing quadruple therapy, Vonoprazan fumarate 20 mg, colloidal bismuth pectin capsule 200 mg , amoxicillin 1000 mg and clarithromycin 500 mg, twice daily, 14 days.Patients will receive oral and written education
Wechat group
EXPERIMENTALPatients in this group will receive clarithromycin based bismuth-containing quadruple therapy, Vonoprazan fumarate 20 mg, colloidal bismuth pectin capsule 200 mg ,amoxicillin 1000 mg and clarithromycin 500 mg, twice daily, 14 days.Patients will receive oral and written education. And patients will be invited into a Wechat group to obtain interactive education through question and answer,which is provided by medical professionals.
Interventions
Wechat group: oral and written education plus Wechat group based interactive education provided by medical professional
Eligibility Criteria
You may qualify if:
- aged between 18 and 75 years old;
- H. pylori infection confirmed by any two positive outcomes of rapid urease test (RUT), 13C-urea breath test (UBT) or histopathology.
You may not qualify if:
- previous therapy for H. pylori;
- with significant underlying disease (e.g. decompensated liver cirrhosis, renal failure or malignant tumors) that may interfere the study;
- history of gastric surgery,
- pregnancy or lactation;
- the use of PPI or antibiotics during the 4 weeks prior to enrolment;
- previous history of allergic reactions to any of the medications used in this protocol;
- unable to use smartphone and wechat
- unwilling or incapable to provide informed consents.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Qilu hosipital
Jinan, Shandong, 257000, China
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Masking Details
- The interventions are blind to follow-up personnel who collect and analyze compliance and the incidence of adverse events. The interventions are also blind to the UBT personnel.
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor, Director of gastroenterology department of Qilu hospital
Study Record Dates
First Submitted
April 7, 2021
First Posted
April 20, 2021
Study Start
July 23, 2021
Primary Completion
August 10, 2022
Study Completion
September 10, 2022
Last Updated
January 31, 2023
Record last verified: 2023-01